secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001193125-22-061344
Event type: earnings
Sentiment:  neutral
Materiality: 0.30
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab reports FY2021 results; financial details not provided in 8-K exhibit
-----------------------------------------------------------------------------

- Announced financial results for FY2021; specific revenue and EPS figures not provided in the filing.
- Forecasts peak-year sales from lung and GI cancer franchises could reach $2.5–3B by 2030.
- Proposed share subdivision of ordinary shares (1:10) to increase liquidity on HKEX; shareholder vote sought.
- Plans to submit NDA for efgartigimod in gMG in China in mid-2022; multiple clinical milestones.
- Entered license agreements for KarXT (neuroscience) and BLU-945/701 (EGFR NSCLC) in Greater China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000119312522061344/0001193125-22-061344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000119312522061344/d258445d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-061344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer